Treatment of Squamous Cell Carcinoma With Intralesional 5-Fluorouracil

Morse, Lisa; Kendrick, Christina G; Hooper, Deirdre; Ward, Holly; Parry, Edward L.

doi:10.1097/00042728-200311000-00018

Cited by 8 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A related study led by Kraus and colleagues 96 demonstrated a 96% clearance rate of SCCs treated with up to 1.0 mL of 5‐FU/epi gel weekly for up to 6 weeks. Morse and coworkers 97 describe a case of a large keratoacanthomatous SCC of the alar crease that cleared after eight weekly injections with dosing ranging from 0.8 to 2.4 mL of 5‐FU. In all studies treatment was well tolerated with excellent cosmesis.…”

mentioning

confidence: 99%

Nonsurgical Treatment Modalities for Primary Cutaneous Malignancies

Tull

Nunley

Sengelmann

2008

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Nonsurgical Treatment Modalities for Primary Cutaneous Malignancies

Tull

Nunley

Sengelmann

2008

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…A subsequent larger study of 116 lesions reported a complete response rate of 91% to intralesional 5‐FU, as demonstrated by post‐treatment excisional biopsy 131 . SCC has also shown good response to 5‐FU, even with larger lesions 132,133 . In general, intralesional 5‐FU in a bovine collagen matrix may offer the promise of a simple and effective technique for management of BCC and SCC, although long‐term outcome data are lacking at the present time.…”

Section: Traditional Non‐surgical Therapiesmentioning

confidence: 94%

“…131 SCC has also shown good response to 5-FU, even with larger lesions. 132,133 In general, intralesional 5-FU in a bovine collagen matrix may offer the promise of a simple and effective technique for management of BCC and SCC, although long-term outcome data are lacking at the present time. This technique, although not yet reported on eyelid tumours, certainly seems to be a promising nonsurgical therapy for patients with periocular SCC and BCC who are resistant to surgery or who are not surgical candidates.…”

Section: -Fluorouracilmentioning

confidence: 99%

Non-surgical treatments of primary, non-melanoma eyelid malignancies: a review

Murchison

Walrath

Washington

2011

Clinical &Amp; Experimental Ophthalmology

View full text Add to dashboard Cite

The diagnosis and management of periocular cutaneous malignancies are essential components of an ophthalmologist's practice. Skin cancers comprise nearly one-third of newly diagnosed malignancies. Furthermore, the incidence of skin cancer appears to be increasing. Multiple treatment modalities exist for periocular cutaneous malignancy. Surgical extirpation, often with the combined expertise of a Mohs micrographic surgeon, is typically the first line therapy and is often curative in the periocular region, depending on a variety of factors, including tumour histology, specific location, depth of invasion and surgical technique. However, there are instances where a less invasive, non-surgical treatment option is warranted, including patients who are poor surgical risks or those with diffuse disease. The purpose of this article is to review the literature and describe the non-surgical treatment options, indications and efficacies for non-melanoma primary eyelid malignancies.

show abstract

“…yaptıkları çalışmada 41 keratoakantoma haftada bir, 50 mg/ml dozunda 5-FU'i İL olarak uygulamış, 40 lezyonun (%97,5) ortalama üç enjeksiyon sonrası tamamen düzeldiğini ve takip süresince de nüks gözlenmediğini bildirmişlerdir (2). Bildirilen diğer olgu sunumlarında da, haftada bir yapılan ve uygulama dozlarının 0,2-3 ml arasında (10-150 mg/doz) değiştiği İL tedavinin, üç ile sekiz arasında değişen sayılarda tekrarı ile tüm hastalarda tam remisyon sağladığı ve nüks gözlenmediği rapor edilmiştir (3)(4)(5)(6). Farklı tedavi yaklaşımları tariflenmekle birlikte, keratoakantom tedavisindeki temel yaklaşım cerrahi eksizyondur.…”

Section: -Fluorourasil (5-fu)unclassified

Intralesional Use of Chemotherapeutic and Biological Drugs in Dermatology

Çalışkan¹,

Özmen²,

Açıkgöz³

et al. 2014

tdd

View full text Add to dashboard Cite

Dermatoloji pratiğinde sıkça kullanılmakta olan intralezyonel enjeksiyon uygulamaları, öncelikle steroidlerin sistemik yan etkilerinden korunmak amacıyla geliştirilmiştir. İntralezyonel uygulamalar, potent ilaçların sistemik toksisiteler göstermeden bölgesel olarak yüksek konsantrasyonda etki göstermelerine olanak sağlamaktadır. Bilindiği gibi sistemik olarak kullanılan kemoterapötik ilaçlar birçok yan etki ve sitotoksisite potansiyeline sahiptir. Kemoterapötik ilaçların cerrahi tedavinin kontrendike olduğu veya fonksiyonel ve kozmetik kayıpla sonuçlanabilecek yerleşimlerdeki non-melanom deri kanserleri tedavisinde intralezyonel kullanımları zamanla yaygınlaşmaktadır. Bu makalede, kemoterapötik ve biyolojik ilaçların intralezyonel kullanımları, avantaj ve dezavantajları, uygulanan ilaçlar ve miktarları, etkinlik ve güvenlik profilleri özetlenmiş olup, bu tür uygulamaların dermatologlar tarafından daha sık uygulanır hale getirilmesi amaçlanmıştır.

show abstract

Treatment of Squamous Cell Carcinoma With Intralesional 5-Fluorouracil

Cited by 8 publications

References 16 publications

Nonsurgical Treatment Modalities for Primary Cutaneous Malignancies

Nonsurgical Treatment Modalities for Primary Cutaneous Malignancies

Non-surgical treatments of primary, non-melanoma eyelid malignancies: a review

Intralesional Use of Chemotherapeutic and Biological Drugs in Dermatology

Contact Info

Product

Resources

About